ライフサイエンスコーパス: elvitegravir

1 resistance to dolutegravir, raltegravir, and elvitegravir.

2 and the integrase inhibitors raltegravir and elvitegravir.

3 istance to the other INSTIs, raltegravir and elvitegravir.

4 lthough resistance was generally greater for elvitegravir.

5 ninferior (-1.44 log(10) copies/mL), and the elvitegravir 125 mg arm was superior (-1.66 log(10) copi

6 eceive a once-a-day single-tablet containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 20

7 the available fixed-dose oral formulation of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 20

8 by their parent or carer) containing 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, a

9 ve once-daily oral tablets containing 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, a

10 endent data monitoring committee stopped the elvitegravir 20 mg arm and allowed subjects in the elvit

11 M), L-870,810 (2.4 nM), raltegravir (10 nM), elvitegravir (4.0 nM), and GSK364735 (2.5 nM).

12 gravir 20 mg arm and allowed subjects in the elvitegravir 50 mg and 125 mg arms to add protease inhib

13 the CPI/r arm (-1.19 log(10) copies/mL), the elvitegravir 50 mg arm was noninferior (-1.44 log(10) co

14 0 nM vs 4 nM), raltegravir (300 nM vs 9 nM), elvitegravir (90 nM vs 6 nM), and GSK364735 (90 nM vs 6

15 three FDA-approved drugs, raltegravir (RAL), elvitegravir and dolutegravir (DTG), act as interfacial

16 the end of the dosing interval (AUCtau) for elvitegravir and the AUC from time zero to the last quan

17 the end of the dosing interval (AUCtau) for elvitegravir and the AUC from time zero to the last quan

18 approval of the second integrase inhibitor, elvitegravir, and a novel pharmacoenhancer cobicistat is

19 are in clinical trials, and raltegravir and elvitegravir are likely to be the first licensed drugs o

20 ndings demonstrate that both raltegravir and elvitegravir are potent IN inhibitors and are highly sel

21 without T-20 and either CPI/r or once-daily elvitegravir at a dose of 20 mg, 50 mg, or 125 mg (blind

22 nsistent with the binding of raltegravir and elvitegravir at the IN-DNA interface.

23 It also confers cross-resistance to elvitegravir but less to G-quadraduplex inhibitors such

24 use at screening) to switch to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir (

25 The single-tablet, fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir a

26 The elvitegravir, cobicistat, emtricitabine, and tenofovir a

27 his single-tablet, fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir a

28 NTERPRETATION: The fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir a

29 Exposures to the elvitegravir, cobicistat, emtricitabine, and tenofovir a

30 Exposures to elvitegravir, cobicistat, emtricitabine, and tenofovir a

31 ablet integrase inhibitor regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir d

32 months after the initiation of therapy with elvitegravir, cobicistat, emtricitabine, and tenofovir d

33 omen were randomly assigned (1:1) to receive elvitegravir, cobicistat, emtricitabine, and tenofovir d

34 Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir d

35 Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir m

36 igned (2:1) either to switch to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir o

37 Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir s

38 fumarate (tenofovir) regimen to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir.

39 fected adults which compared the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoprox

40 There was no relationship between elvitegravir dosage and adverse events.

41 g, and an HIV-1 genotype with sensitivity to elvitegravir, emtricitabine, and tenofovir.

42 lls per muL, and no history of resistance to elvitegravir, emtricitabine, tenofovir alafenamide, or t

43 altegravir (RAL) (October 2007) and Gilead's Elvitegravir (EVG) (August 2012), which act as IN strand

44 The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A

45 The integrase inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A

46 Elvitegravir (EVG), RPV, and darunavir (DRV) concentrati

47 HIV activity) and a new integrase inhibitor, elvitegravir (EVG).

48 or susceptibilities to raltegravir (RAL) and elvitegravir (EVG).

49 r inhibitors (INSTIs), raltegravir (RAL) and elvitegravir (EVG).

50 emtricitabine, and either cobicistat-boosted elvitegravir (EVGcobi), rilpivirine (RPV), or ritonavir-

51 drug raltegravir (MK-0518, Isentress) while elvitegravir (GS-9137, JTK-303) is in clinical trials.

52 e the resistance profile for raltegravir and elvitegravir in those IN mutants.

53 ed cross-resistance to raltegravir (RAL) and elvitegravir in vitro.

54 The results show raltegravir, elvitegravir, MK-2048, RDS 1997, and RDS 2197 all appear

55 e the resistance pathways to raltegravir and elvitegravir (N155H, Q148K/R/H, and E92Q) were either ra

56 e and compare the effects of raltegravir and elvitegravir on the three IN-mediated reactions, 3'-proc

57 ase strand transfer inhibitor (dolutegravir, elvitegravir, or raltegravir), a nonnucleoside reverse t

58 tients had viruses with >/= 1 raltegravir or elvitegravir resistance mutation (15.6%).

59 cted in 12% of patients with raltegravir- or elvitegravir-resistant viruses (2% of all patients).

60 Y conferred relatively greater resistance to elvitegravir than raltegravir.

61 heir failing regimen (without raltegravir or elvitegravir) through day 7, after which the regimen was

62 nodeficiency virus (HIV) integrase inhibitor elvitegravir to comparator ritonavir-boosted protease in

63 The mean AUCtau for elvitegravir was 23 840 ng x h per mL (coefficient of va

64 The mean AUCtau of elvitegravir was 33 814 ng x h/mL (coefficient of variat

65 Elvitegravir was more potent than raltegravir, but neith

66 Elvitegravir was well-tolerated and produced rapid virol